Literature DB >> 2121685

Inactivation of human tumor cell pro-urokinase by granulocyte elastase.

N Kanayama1, T Terao.   

Abstract

Supernatant obtained from granulocytes stimulated in the presence of cytochalasin B by the chemotactic peptide N-formyl-norleucyl-leucyl-phenylalanyl-norleucyl-tyrosyl- lysine displayed an inhibitory effect on the plasmin-dependent conversion of tumor urokinase-type plasminogen activator proenzyme (pro-uPA) to the active form of uPA. Moreover, the supernatant was also found to inhibit the fibrinolytic activity of human vulva (A431) and breast (MCF7) carcinoma cell lines, which contain large amounts of pro-uPA, by 87% and 96%, respectively. By using eglin C (elastase inhibitor) and a monoclonal antibody to elastase (proteolytic activity blocker of the enzyme), elastase was identified as the key enzyme of the supernatant in these phenomena. Purified elastase converted pro-uPA to an enzymatically inactive molecule composed of two polypeptide chains of Mr = 33,000 and 22,000 linked to each other by a disulfide bond. Elastase-containing granulocytes were identified by immunohistochemistry techniques in the tissues of squamous cell carcinoma and adenocarcinoma of uterus. The cells were found close to the tumor cells and in the stroma surrounding the tumor nests. By immunohistochemical staining, uPA was also found in the tumor cells. Evidently, elastase released by chemotactically activated granulocytes, which are attracted into tumor tissues, may inhibit the conversion of pro-uPA to enzymatically active uPA in the tumor cells.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2121685      PMCID: PMC5917968          DOI: 10.1111/j.1349-7006.1990.tb03337.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  29 in total

1.  Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937.

Authors:  E K Kruithof; J D Vassalli; W D Schleuning; R J Mattaliano; F Bachmann
Journal:  J Biol Chem       Date:  1986-08-25       Impact factor: 5.157

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  Plasminogen activator activity and composition in human breast cancer.

Authors:  J L Evers; J Patel; J M Madeja; S L Schneider; G H Hobika; S M Camiolo; G Markus
Journal:  Cancer Res       Date:  1982-01       Impact factor: 12.701

4.  Influence of detergents on the measurement of the fibrinolytic activity of plasminogen activators.

Authors:  E K Kruithof; A Ransijn; F Bachmann
Journal:  Thromb Res       Date:  1982-10-15       Impact factor: 3.944

5.  Immunologic rejection of mammary adenocarcinoma (TA3-St) in C57BL/6 mice: participation of neutrophils and activated macrophages with fibrin formation.

Authors:  A M Dvorak; A B Connell; K Proppe; H F Dvorak
Journal:  J Immunol       Date:  1978-04       Impact factor: 5.422

6.  Purification and characterization of single-chain urokinase-type plasminogen activator (pro-urokinase) from human A431 cells.

Authors:  A Corti; M L Nolli; A Soffientini; G Cassani
Journal:  Thromb Haemost       Date:  1986-10-21       Impact factor: 5.249

7.  Plasminogen activator profiles in neoplastic tissues of the human colon.

Authors:  P A de Bruin; G Griffioen; H W Verspaget; J H Verheijen; G Dooijewaard; H F van den Ingh; C B Lamers
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

8.  Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.

Authors:  G Markus; H Takita; S M Camiolo; J G Corasanti; J L Evers; G H Hobika
Journal:  Cancer Res       Date:  1980-03       Impact factor: 12.701

9.  Isolation and characterization of plasminogen activators from hyperplastic and malignant prostate tissue.

Authors:  J Kirchheimer; A Köller; B R Binder
Journal:  Biochim Biophys Acta       Date:  1984-02-14

10.  Human neutrophil-mediated cytotoxicity to tumor cells.

Authors:  T L Gerrard; D J Cohen; A M Kaplan
Journal:  J Natl Cancer Inst       Date:  1981-03       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.